Oxford BioMedica PLC (OXBDF)

[marcusl2]

Tom Whitehead, father of emily (patient #1) to speak at ctl-19 approval hearing on July 12.

Love this bit: "With FDA approval, the CTL019 CAR-T cell therapy would no longer be constrained to clinical trials—effectively making this life-saving cancer immunotherapy treatment accessible to many more children around the world! "


http://emilywhiteheadfoundation.org/tom-whitehead-to-speak-at-fda-approval-hearing-car-t-cell-therapy-ctl019/

British company Oxford BioMedica is the sole manufacturer of the lentiviral vector expressing CTL019 for Novartis. The commercial launch of CTL019 is anticipated by Novartis later this year and Oxford BioMedica will receive undisclosed royalties on potential future sales of Novartis CAR-T products.

Oxford Biomedica are developing further immunotherapies with Novartis for many other cancers.
http://www.oxfordbiomedica.co.uk/investor-contacts/